Research
Hormonal
Liraglutide and semaglutide are the only approved anti-obesity medications demonstrated to lower the risk of major cardiovascular events in patients with or without established cardiovascular disease.
For patients with obesity and existing heart disease or diabetes, Liraglutide (3mg daily) and Semaglutide (2.4mg weekly) are preferred because they reduce cardiovascular event risk, unlike other weight loss drugs.
StrongSupportsHIGH confidence
Although all anti-obesity medications have been demonstrated to improve cardiometabolic risk factors, only liraglutide and semaglutide lower the risk of major cardiovascular events in patients with or without established cardiovascular disease.
Why this rating
Cited as a primary advantage with specific trial references.
Source
Pharmacotherapy of obesity: State of the art and perspectives
Katarina Sićović et al. · Arhiv za farmaciju · 2024
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →